FDA Expands ZORYVE Pediatric Label; Focus Shifts to Q2 Execution

What happened

On June 29, 2026, the FDA approved Arcutis' ZORYVE (roflumilast) cream 0.3% for plaque psoriasis in children as young as 2, marking the seventh ZORYVE approval. This expands the treatable population and removes a key regulatory catalyst, but the near-term thesis now hinges on Q2 net product revenue rebounding from Q1's $105.4M (down 17% QoQ due to deductible resets) and sustaining positive operating cash flow. The approval was widely anticipated and priced into the bull scenario; the real test is whether the expanded label and internal primary care/pediatrics salesforce can convert into sequential revenue growth. If Q2 revenue fails to re-accelerate above $115M, the stock may face selling pressure as the catalyst is exhausted without fundamental backing.

Implication

The pediatric psoriasis approval is a positive but expected milestone. The company now must demonstrate that the expanded label, combined with its newly internalized primary care/pediatrics salesforce, drives measurable script and revenue growth in Q2 and beyond. Any weakness in Q2 results (revenue below $115M, negative operating cash flow) would undermine the bull case and likely trigger de-rating. Conversely, strong execution could push ARQT toward the $32 bull case. Key metrics to monitor: weekly TRx (~21k), BNST share (~48%), and gross-to-net trends.

Thesis delta

The pediatric psoriasis approval removes one of the two near-term catalysts identified in the master report (alongside Q2 revenue re-acceleration). The thesis shifts from 'approval upside' to 'commercial execution proof' — specifically, whether the expanded label and primary care sales build can convert into sequential revenue growth above Q1's $105.4M and sustained positive operating cash flow. The bull scenario's probability may increase if Q2 results confirm growth, but the bear risk (SG&A rising faster than revenue) remains if revenue disappoints.